Pharming Group (PHAR) Osake Kurssi

Pharming Group NV is a biopharmaceutical company based in Leiden, Netherlands, listed on the stock market with the ticker PHAR and ISIN US71716E1055. The company operates in the Health Care sector, specifically within the Health Care industry, and employs approximately 1,800 people. Pharming Group NV went public through an IPO on December 23, 2020. Its website is https://www.pharming.com. The company focuses on developing and commercializing protein replacement therapies and precision medicines for rare diseases. While the provided source mentions specific products like RUCONEST and Joenja, these details are treated as untrusted facts and are not included in this profile. Pharming Group NV is incorporated in the United States, though it is headquartered in Leiden, Netherlands. The company has a development collaboration and license agreement with Novartis, as noted in the source. Pharming Group NV's activities span the United States, Europe, and internationally. The company's primary focus is on rare diseases, and it is engaged in the research, development, and commercialization of innovative therapeutic solutions. The company's corporate structure and operations are centered around its headquarters in Leiden, with a global reach in the healthcare market. The exact founding year is not provided in the user message, so it is omitted from this profile. The company's product pipeline and specific therapeutic areas are not detailed beyond the general focus on rare diseases.